SCHEMBL1075415

SCHEMBL1075415

C#CS(=O)(=O)c1ccccc1

nearest known ligand 0.50

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
HTR6 P50406 2/20 0.50
CA1 P00915 3/20 0.46
CA2 P00918 3/20 0.46
TDP1 Q9NUW8 2/20 0.46
CA12 O43570 2/20 0.46
CA9 Q16790 2/20 0.46
CA14 Q9ULX7 2/20 0.46
ALDH1A1 P00352 2/20 0.46
HSD17B10 Q99714 1/20 0.46
CA3 P07451 1/20 0.46
CA4 P22748 1/20 0.46
CA6 P23280 1/20 0.46
CA5A P35218 1/20 0.46
CA7 P43166 1/20 0.46
PLA2G7 Q13093 1/20 0.46
CA13 Q8N1Q1 1/20 0.46
CA5B Q9Y2D0 1/20 0.46
TSHR P16473 1/20 0.46
SMN1; SMN2 Q16637 1/20 0.46
DUSP3 P51452 1/20 0.44

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL10656231 0.78 HTR6 (0.55) HTR6CA1CA2TDP1CA12
SCHEMBL7124034 0.76 HTR6 (0.52) HTR6CA1CA2TDP1CA12
SCHEMBL19181037 0.75 MMP2 (0.45) CA1CA2ALDH1A1TSHRMMP1
SCHEMBL1721592 0.75 GAA (0.54) CA1CA2TDP1CA12CA9
SCHEMBL7456723 0.75 ALDH1A1 (0.54) CA1CA2TDP1CA12CA9
SCHEMBL7452249 0.75 CA2 (0.50) CA1CA2CA12CA9CA14
SCHEMBL2045248 0.74 HTR6 (0.50) HTR6CA1CA2TDP1CA12
SCHEMBL7360791 0.74 HTR6 (0.50) HTR6CA1CA2TDP1CA12
SCHEMBL15873589 0.74 HTR6 (0.50) HTR6CA1CA2TDP1CA12
SCHEMBL9540908 0.74 HTR6 (0.50) HTR6CA1CA2TDP1CA12

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 105 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-12046717-B2 Nonaqueous electrolyte compositions comprising a fluorinated solvent and a 2-furanone SYENSQO SA (BE) 2024-07-23 US claimed
EP-3643706-B1 MODIFIED NUCLEIC ACID MONOMERS AND OLIGONUCLEIC ACID ANALOGUES, WITH HIGH BIOLOGICAL STABILITY AND TARGET GENE SILENCING ACTIVITY, FOR USE IN THERAPY AND DIAGNOSIS OF CANCER AND VIRAL DISEASES EISAI R&D MAN CO LTD (JP) 2023-11-15 EP claimed
EP-3606528-B1 TRICYCLIC COMPOUNDS AS GLYCOGEN SYNTHASE KINASE 3 (GSK3) INHIBITORS AND USES THEREOF BROAD INST INC (US) 2023-10-18 EP claimed
EP-3172213-B1 MACROCYCLIC KINASE INHIBITORS AND USES THEREOF DANA FARBER CANCER INST INC (US) 2021-09-22 EP claimed
EP-3398952-B1 SYNTHESIS PROCESS OF RUXOLITINIB CHIA TAI TIANQING PHARMACEUTICAL GROUP CO LTD (CN) 2021-07-14 EP claimed
EP-3473625-B1 PREPARATION METHOD FOR CHIRAL PYRROLOPYRIMIDINE COMPOUND CHIA TAI TIANQING PHARMACEUTICAL GROUP CO LTD (CN) 2021-06-02 EP claimed
EP-3191479-B1 \"PROCESS FOR THE PREPARATION OF MACROCYCLIC KETONE ANALOGS OF HALICHONDRIN B OR PHARMACEUTICALLY ACCEPTABLE SALTS AND INTERMEDIATES THEREOF\ CIPLA LTD (IN) 2020-04-08 EP claimed
EP-2921499-B1 METHOD FOR LIQUID-PHASE SYNTHESIS OF NUCLEIC ACIDS TAKEDA PHARMACEUTICALS CO (JP) 2020-01-22 EP claimed
EP-3089980-B1 SERINE/THREONINE KINASE INHIBITORS ARRAY BIOPHARMA INC (US) 2018-01-31 EP claimed
EP-2727915-B1 Synthesis of deuterated catechols and benzo[d][1,3]dioxoles and derivatives thereof CONCERT PHARMACEUTICALS INC (US) 2016-04-13 EP claimed
US-20130289104-A1 ALIPHATIC AMINO ACID BIOSYNTHESIS INHIBITORS AND A METHOD OF SYNTHESIZING THE SAME Sardari, Soroush (IR) 2013-10-31 US claimed
US-8569361-B1 Aliphatic amino acid biosynthesis inhibitors and a method of synthesizing the same SARDARI SOROUSH (IR) 2013-10-29 US claimed
EP-2066662-B1 SERINE HYDROLASE INHIBITORS KYORIN SEIYAKU KK (JP) 2012-12-05 EP claimed
EP-1496892-B1 1H-BENZO(F)INDAZOL-5-YL DERIVATIVES AS SELECTIVE GLUCOCORTICOID RECEPTOR MODULATORS MERCK SHARP & DOHME (US) 2011-01-26 EP claimed
EP-2125718-B1 NEW SUBSTITUTED ARYLSULPHONYLGLYCINES, THE PREPARATION THEREOF AND THE USE THEREOF AS PHARMACEUTICAL COMPOSITIONS BOEHRINGER INGELHEIM INT (DE) 2010-09-15 EP claimed
EP-1511760-B1 CARBOXY PROTECTION STRATEGIES FOR ACIDIC C-TERMINAL AMINO ACIDS IN CHEMICAL LIGATION OF OLIGOPEPTIDES GENEPROT INC (CH) 2006-01-18 EP claimed
EP-0194984-B1 DERIVATIVES OF IMIDAZOLE, THEIR PREPARATION AND UTILISATION, AND PHARMACEUTICAL COMPOSITIONS CONTAINING THESE DERIVATIVES CONTINENTAL PHARMA, INC. (BE) 1990-04-04 EP claimed
US-12148889-B2 Non-aqueous electrolyteincluding lithium bis(fluorosulfonyl)imide, fluorinated acyclic carboxylic acid ester, organic carbonate and electrolyte salt SYENSQO SA (BE) 2024-11-19 US disclosed
WO-2000056305-A1 ALKYNYL ARYL SULFONES LONZA INC. (US) 2000-09-28 WO disclosed
WO-1994022868-A1 7-AZABICYCLO-[2.2.1]-HEPTANE AND -HEPTENE DERIVATIVES AS ANALGESICS AND ANTI-INFLAMMATORY AGENTS UNIVERSITY OF VIRGINIA (US) 1994-10-13 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20130289104-A1 ALIPHATIC AMINO ACID BIOSYNTHESIS INHIBITORS AND A METHOD OF SYNTHESIZING THE SAME DDC, BCAT2, BCAT1 HTR6 3596/4885CA1 2055/4885CA2 1990/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.